Impact55 2026 runner-up: Serenatis Bio

Impact55 runner-up, Serenatis Bio, is developing three new medications to treat obsessive compulsive disorder (OCD) by targeting the neurological pathways that drive the condition. With more than 240m people worldwide affected by OCD and no new drug classes introduced since the 1990s, the company aims to deliver treatments that work faster and more effectively than current options such as SSRIs and antipsychotics.

You can find out more about Serenatis Bio and the work they are doing here: https://serenatisbio.com/